Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Business Wire (Tue, 21-Jul 6:30 AM ET)
Business Wire (Mon, 8-Jun 6:30 AM ET)
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting
Business Wire (Wed, 3-Jun 5:45 PM ET)
Business Wire (Thu, 7-May 6:30 AM ET)
Stevanato Group to Participate in Three Upcoming Investor Conferences
Business Wire (Mon, 4-May 5:45 PM ET)
Market Chameleon (Wed, 4-Mar 4:28 AM ET)
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
Stevanato Group S.P.A. trades on the NYSE stock market under the symbol STVN.
As of July 24, 2026, STVN stock price climbed to $19.68 with 315,595 million shares trading.
STVN has a beta of 1.54, meaning it tends to be more sensitive to market movements. STVN has a correlation of 0.25 to the broad based SPY ETF.
STVN has a market cap of $5.37 billion. This is considered a Mid Cap stock.
Last quarter Stevanato Group S.P.A. reported $320 million in Revenue and $.13 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.01.
In the last 3 years, STVN traded as high as $36.30 and as low as $12.89.
The top ETF exchange traded funds that STVN belongs to (by Net Assets): IBB, KOMP, NBSM, BCSM, SMLV.
STVN has underperformed the market in the last year with a return of -22.3%, while SPY returned +17.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in STVN shares. However, STVN has outperformed the market in the last 3 month and 2 week periods, returning +21.6% and -0.4%, while SPY returned +4.6% and -1.7%, respectively. This indicates STVN has been having a stronger performance recently.
STVN support price is $18.77 and resistance is $20.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STVN shares will trade within this expected range on the day.